The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 05, 2010
Filed:
Aug. 04, 2008
David J Cosman, Bainbridge Island, WA (US);
Jurgen Mullberg, Cambridge, MA (US);
William C Fanslow, Iii, Normandy Park, WA (US);
Marek Z Kubin, Bainbridge Island, WA (US);
Richard J Armitage, Bainbridge Island, WA (US);
David J Cosman, Bainbridge Island, WA (US);
Jurgen Mullberg, Cambridge, MA (US);
William C Fanslow, III, Normandy Park, WA (US);
Marek Z Kubin, Bainbridge Island, WA (US);
Richard J Armitage, Bainbridge Island, WA (US);
Immunex Corporation, Thousand Oaks, CA (US);
Abstract
The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity.